Strategic focus Targeting deubiquitylating enzymes (DUBs) with a world-leading small-molecule platform presents a unique entry point for partnerships or licensing deals in first-in-class therapies, particularly for neurodegenerative, mitochondrial, fibrosis, and kidney disease indications.

Clinical momentum Active lead assets such as MTX652 progressing toward Phase II for Acute Kidney Injury and ongoing collaboration potential with Parkinson's research initiatives indicate opportunities to co-develop or out-license programs aligned with investor and patient advocacy networks.

Strategic partnerships Strong ties with Cancer Research UK Laboratories, Jackson Laboratories, and foundations like MJFF and Parkinson’s UK create collaboration channels for co-funded studies, translational research access, and joint grant-enabled expansion of DUB-focused programs.

Funding signals Recent Series D funding and grants from Innovate UK and Parkinson’s-focused groups signal investor appetite for DUB biology and attract potential co-investors or strategic partners seeking late-stage preclinical/clinical collaboration or portfolio acceleration.

Geographic footprint Based in the Babraham Research Campus near Cambridge with a footprint shifting toward broader European operations suggests opportunities for regional clinical trial sites, CRO partnerships, and manufacturing collaborations to scale DUB programs efficiently.